[Clinical observation of taxotere in the treatment of advanced non-small-cell lung cancer and breast cancer].
To observe the response rate and toxic reaction of taxotere in the treatment of advanced NSCLC and breast cancer. A total of 24 cases was included in the study. Taxotere 75 mg/m2 i.v. drip for 1 hour; dexamethasone 8 mg bid 24 hour before taxotere, and continued for 3 days. For NSCLC, the taxotere was combined with DDP 90 mg/m2; for breast cancer, it was combined with ADM 40 mg/m2. The second treatment cycle was given after 3 weeks. At last 2 cycles were given. In 15 NSCLC patients, there were 6 PR, 7 NC and 2 PD. In 9 breast cancer patients, there were 2 CR, 6 PR and 1 NC. The major toxic reactions were neutropenia, diarrhea, fatigue, muscle pain and alopecia. Grade 3 and grade 4 neutropenia occurred in 9 and 4 cases, respectively. Decrease in hemoglobin and thrombocytopenia were mild. Diarrhea occurred in 19 cases and allergic reaction in 1 case. Taxotere is effective in the combined treatment of advanced NSCLC and breast cancer. The toxic reactions are tolerable.